Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

Looking to cement its spot in the burgeoning realm of radiopharmaceuticals, Florida-based contract manufacturer PharmaLogic ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S ...